COFC Finds it Lacks Jurisdiction to Hear Bid Protest Challenging Evaluation and Award of Prototype OTA
Client Alert | 1 min read | 09.09.19
On August 28, 2019, in a case of first impression, the Court of Federal Claims held in Space Exploration Technologies Corp. v. United States that the Court lacks subject-matter jurisdiction over a protest challenging the awards of launch service agreements (“LSAs”) issued under the Department of Defense’s prototype other transaction (“OT”) authority. The protester, SpaceX, challenged the Air Force’s evaluation and portfolio award decisions under a solicitation for prototype OTs to facilitate and fund the development of U.S. launch systems by the awardees. SpaceX, which did not receive an award, argued that because the challenged LSA awards were expected to lead to the development of launch vehicles that would likely be offered by the awardees in a subsequent Phase II competition, the awards of the challenged LSAs were in connection with a procurement or proposed procurement, and, therefore, the Court had jurisdiction under the Tucker Act. The Court, however, disagreed and found that the prototype OT evaluation and award decisions for the LSAs were not “in connection with” the anticipated Phase 2 procurement for a number of reasons, including that the competitions involved separate and distinct solicitations, different acquisition strategies, and different goals (i.e., the LSA competition focused on increasing the pool of potential launch vehicles, whereas the Phase 2 procurement would procure launch services). Although the Court dismissed the complaint, the Court transferred venue to a district court to permit SpaceX to pursue its claims in an appropriate jurisdiction.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection



